Organon & Co. Common Stock · Transaction Aug 5, 2026 · Filed Aug 12, 2026 · $1,001 to $15,000
NEW YORK STOCK EXCHANGE, INC. · OGN
+0.07% · +$0.0100 · Vol 1.9M
Market closed · last close 4:00 PM ET · price as of 19:00:00 ET
Organon & Co
Pharmaceuticals
$13.72
Follow $OGN
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $OGN by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredFri Oct 2 · last completed session · Markets closed · resumes Mon 9:30 ET · OGN
MethodologyOGN
Organon & Co
Fri Oct 2 · last completed session · Markets closed · resumes Mon 9:30 ET
Upper range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
60/ 100
Veridion Score
Upper range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Fri Oct 2 · last completed session · Markets closed · resumes Mon 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is OGN moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Organon & Co
PHARMACEUTICAL PREPARATIONSListed since
2021
Employees
10K
Country
US
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$13.71
Day high
$13.75
Day low
$13.71
Previous close
$13.71
52W high
$13.78
-0.44% from high
52W low
$5.70
99% of range
Market cap
$3.6B
P/E
17.24×
EPS
$2.12
Beta
0.06
Shares out
262.6M
Volume
1.9M
0.70× rel vol
Avg volume
2.8M
VWAP
$13.72
Price history computed in-house
1W
-0.07%
1M
-0.36%
3M
+1.25%
1Y
+24.61%
YTD
+91.35%
SMA 50 $13.68 · above
SMA 200 $10.89 · above
52W position 99%
OGN overview
Related filings and maps
Public disclosures
Congress activity in OGN
Official filing ↗
Organon & Co. · Transaction Jul 10, 2025 · Filed Nov 24, 2025 · $1,001 to $15,000
Organon & Co. · Transaction Jun 28, 2021 · Filed Jul 9, 2021 · $1,001 to $15,000
Federal contracts
OGN contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for OGN in this window.
Lobbying spend
OGN lobbying filings, year to date.
Registered lobbying filings matched to Organon & Co.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for OGN in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for OGN.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.